Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 124

1.

Assessment of Azeliragon QTc Liability Through Integrated, Model-Based Concentration QTc Analysis.

Burstein AH, Brantley SJ, Dunn I, Altstiel LD, Schmith V.

Clin Pharmacol Drug Dev. 2019 May;8(4):426-435. doi: 10.1002/cpdd.689. Epub 2019 Apr 1.

PMID:
30934161
2.

Development of Azeliragon, an Oral Small Molecule Antagonist of the Receptor for Advanced Glycation Endproducts, for the Potential Slowing of Loss of Cognition in Mild Alzheimer's Disease.

Burstein AH, Sabbagh M, Andrews R, Valcarce C, Dunn I, Altstiel L.

J Prev Alzheimers Dis. 2018;5(2):149-154. doi: 10.14283/jpad.2018.18.

PMID:
29616709
3.

Early Clinical and Radiographic Outcomes of Trabecular Metal Total Ankle Replacement Using a Transfibular Approach.

Barg A, Bettin CC, Burstein AH, Saltzman CL, Gililland J.

J Bone Joint Surg Am. 2018 Mar 21;100(6):505-515. doi: 10.2106/JBJS.17.00018.

PMID:
29557867
4.

Multiple-dose ponezumab for mild-to-moderate Alzheimer's disease: Safety and efficacy.

Landen JW, Cohen S, Billing CB Jr, Cronenberger C, Styren S, Burstein AH, Sattler C, Lee JH, Jack CR Jr, Kantarci K, Schwartz PF, Duggan WT, Zhao Q, Sprenger K, Bednar MM, Binneman B.

Alzheimers Dement (N Y). 2017 May 10;3(3):339-347. doi: 10.1016/j.trci.2017.04.003. eCollection 2017 Sep.

6.

Effect of TTP488 in patients with mild to moderate Alzheimer's disease.

Burstein AH, Grimes I, Galasko DR, Aisen PS, Sabbagh M, Mjalli AM.

BMC Neurol. 2014 Jan 15;14:12. doi: 10.1186/1471-2377-14-12.

7.

Safety and pharmacology of ponezumab (PF-04360365) after a single 10-minute intravenous infusion in subjects with mild to moderate Alzheimer disease.

Burstein AH, Zhao Q, Ross J, Styren S, Landen JW, Ma WW, McCush F, Alvey C, Kupiec JW, Bednar MM.

Clin Neuropharmacol. 2013 Jan-Feb;36(1):8-13. doi: 10.1097/WNF.0b013e318279bcfa.

PMID:
23334069
8.

A review of the clinical pharmacokinetics and pharmacodynamics of varenicline for smoking cessation.

Faessel HM, Obach RS, Rollema H, Ravva P, Williams KE, Burstein AH.

Clin Pharmacokinet. 2010 Dec;49(12):799-816. doi: 10.2165/11537850-000000000-00000. Review.

PMID:
21053991
9.

Pharmacokinetics, safety, and tolerability following multiple oral doses of varenicline under various titration schedules in elderly nonsmokers.

Zhao Q, Schwam E, Fullerton T, O'Gorman M, Burstein AH.

J Clin Pharmacol. 2011 Apr;51(4):492-501. doi: 10.1177/0091270010370461. Epub 2010 May 13.

PMID:
20466870
10.

Increase in tiagabine serum concentration with coadministration of gemfibrozil.

Burstein AH, Boudreau EA, Theodore WH.

Ann Pharmacother. 2009 Feb;43(2):379-82. doi: 10.1345/aph.1L080. Epub 2009 Feb 3.

PMID:
19193595
11.

Lack of a pharmacokinetic interaction between a new smoking cessation therapy, varenicline, and digoxin in adult smokers.

Faessel HM, Burstein AH, Troutman MD, Willavize SA, Rohrbacher KD, Clark DJ.

Eur J Clin Pharmacol. 2008 Nov;64(11):1101-9. doi: 10.1007/s00228-008-0530-6. Epub 2008 Jul 26.

PMID:
18661125
12.

Human abuse liability of the smoking cessation drug varenicline in smokers and nonsmokers.

McColl SL, Burstein AH, Reeves KR, Billing CB Jr, Stolar M, Sellers EM.

Clin Pharmacol Ther. 2008 Apr;83(4):607-14. doi: 10.1038/sj.clpt.6100510. Epub 2008 Feb 20.

PMID:
18288085
13.

Metabolism and disposition of a gamma-aminobutyric acid type A receptor partial agonist in humans.

Shaffer CL, Gunduz M, Vaz AD, Venkatakrishnan K, Burstein AH.

Drug Metab Dispos. 2008 Apr;36(4):655-62. doi: 10.1124/dmd.107.019760. Epub 2008 Jan 7.

PMID:
18180269
14.

Effect of human renal cationic transporter inhibition on the pharmacokinetics of varenicline, a new therapy for smoking cessation: an in vitro-in vivo study.

Feng B, Obach RS, Burstein AH, Clark DJ, de Morais SM, Faessel HM.

Clin Pharmacol Ther. 2008 Apr;83(4):567-76. Epub 2007 Oct 31.

PMID:
17971819
15.

Lack of pharmacokinetic and pharmacodynamic interactions between a smoking cessation therapy, varenicline, and warfarin: an in vivo and in vitro study.

Burstein AH, Clark DJ, O'Gorman M, Willavize SA, Brayman TG, Grover GS, Walsky RL, Obach RS, Faessel HM.

J Clin Pharmacol. 2007 Nov;47(11):1421-9.

PMID:
17962429
16.
17.

Multiple-dose pharmacokinetics of the selective nicotinic receptor partial agonist, varenicline, in healthy smokers.

Faessel HM, Gibbs MA, Clark DJ, Rohrbacher K, Stolar M, Burstein AH.

J Clin Pharmacol. 2006 Dec;46(12):1439-48.

PMID:
17101743
18.

Pharmacokinetics, safety, and tolerability after single and multiple oral doses of varenicline in elderly smokers.

Burstein AH, Fullerton T, Clark DJ, Faessel HM.

J Clin Pharmacol. 2006 Nov;46(11):1234-40.

PMID:
17050788
19.

Single-dose pharmacokinetics of varenicline, a selective nicotinic receptor partial agonist, in healthy smokers and nonsmokers.

Faessel HM, Smith BJ, Gibbs MA, Gobey JS, Clark DJ, Burstein AH.

J Clin Pharmacol. 2006 Sep;46(9):991-8.

PMID:
16920893
20.

Retrospective evaluation of commonly used equations to predict energy expenditure in mechanically ventilated, critically ill patients.

Alexander E, Susla GM, Burstein AH, Brown DT, Ognibene FP.

Pharmacotherapy. 2004 Dec;24(12):1659-67.

PMID:
15585435

Supplemental Content

Loading ...
Support Center